FindTrial
Sign In

HERA study: A study of Intravenous R597 (Trastuzumab) in Women with HER2-Positive Primary Breast Cancer

HERA study: A study of Intravenous R597 (Trastuzumab) in Women with HER2-Positive Primary Breast Cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220185
Enrollment
Unknown
Registered
2005-12-12
Start date
2005-12-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

investigational material(s) Generic name etc : R597 (Trastuzumab) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Female patients, >=18 years of age, with HER2-positive primary breast cancer; Completion of adjuvant systemic chemotherapy and radiotherapy, if applicable. Exclusion criteria: History of prior invasive breast cancer; Prior use of any anti-HER2 therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary endpoint: Disease free survival (DFS)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026